BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28

• 

  Drug Development

  Efficacy, Safety Concerns Quash Reata’s Alport Syndrome Drug

  The FDA said that the shared NDA documents did not show ample proof that bardoxolone methyl effectively slows down kidney function loss in patients with Alport syndrome.

  February 28, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Drug Development

  New Studies Support Wuhan Wet Market as Origin of COVID-19

  Three new studies have been released—but not yet peer-reviewed—that support the wet market theory relating to COVID-19.

  February 28, 2022

   · 

  4 min read

   · 

  Mark Terry
• 

  Deals

  Biohaven Commits to New Drugs for Epilepsy and SMA

  Biohaven Pharmaceutical Holding announced the acquisition of Channel Bio and new licensing rights to a spinal muscle atrophy drug from Bristol Myers Squibb.

  February 28, 2022

   · 

  3 min read

   · 

  Hannah Chudleigh
• 

  Business

  Celyad Trial Pause Another Setback for CAR-T in Solid Tumors

  Celyad announced that it is voluntarily pausing a clinical trial it’s conducting with Merck after reports of two patient deaths.

  February 28, 2022

   · 

  3 min read

   · 

  Mark Terry
• 

  Policy

  Moderna’s Spikevax Faces Another Patent Challenge

  On Monday, Arbutus and Genevant filed a lawsuit against Moderna challenging patent infringement.

  February 28, 2022

   · 

  3 min read

   · 

  Alex Keown
• 

  Policy

  Judge Approves J&J’s Texas Two-Step Plan to Enable “Expeditious” Compensation

  The decision was intended to resolve the matter as swiftly as possible so that those who claimed to have been harmed by the product could receive expeditious compensation.

  February 28, 2022

   · 

  2 min read

   · 

  Vanessa Doctor, RN
• 

  Deals

  Prioritize Programs and Preserve Resources to Weather 2022 Market Volatility

  That’s the advice for emerging growth life sciences companies in 2022, according to attorney Frank Rahmani, partner in the global life science and capital markets practice group at Sidley Austin LLP.

  February 28, 2022

   · 

  5 min read

   · 

  Gail Dutton
• 

  Career Advice

  Which BioPharma Department is Right For You?

  Discover the most common departments that make up a BioPharma company, learn about the responsibilities of each department and figure out which role is the right fit for you.

  February 28, 2022

   · 

  5 min read

   · 

  Alina Zahid
• 

  Business

  Biocon Buys Viatris’ Biosimilars in $3.3B Deal Aimed at Market Leadership

  Biocon Biologics has acquired its partner Viatris’ biosimilars assets. The transaction is part of an effort to create a global, vertically-integrated biosimilars leader.

  February 28, 2022

   · 

  2 min read

   · 

  Hayley Shasteen
• 

  Job Trends

  Life Science Industry Set Record Pace in 2021

  As we closed the books on year two of the COVID-19 pandemic, the Life Sciences market set records as the strongest in history.

  February 28, 2022

   · 

  2 min read

   · 

  Kate Goodwin